AstraZeneca and Astex Announce Strategic Alliance Focused on Novel Inhibitors Discovered Under a Collaborative Programme Between Astex, The Institute of Cancer Research and Cancer Research Technology
27 July 2005 - AstraZeneca and Astex Therapeutics today announced a new alliance to discover, develop and commercialize novel small molecule inhibitors of Protein Kinase B (PKB; also known as Akt) for use as anti-cancer agents. The Collaboration and License Agreement grants AstraZeneca worldwide rights to PKB inhibitors discovered under Astex’s existing PKB drug discovery collaboration, in part funded by Cancer Research UK, with The Institute of Cancer Research and Cancer Research Technology.
To view the original press release on the Astex website click here.
|
